Sino-Biocan (Shanghai) Biotech Ltd, a provider of automated, modularized, closed cell production platforms for the cell and gene therapy (CGT) sector, has reportedly secured RMB 100 million (USD 14.5 million) in a Series B financing round. The round was led by Dalton Venture, with additional investment from Qikun Fund and JinJue Investment, as well as support from existing investors Neovision Capital, Grand Flight Investment, and Sinovation Ventures. The funds raised will be directed towards constructing a modern manufacturing system, enhancing research and development capabilities, and covering global regulatory filings and market expansion initiatives.
Sino-Biocan provides a suite of seven distinct services across the CGT value chain, partnering with over 100 companies that include CGT R&D firms, hospital translational medicine research centers, and medical anti-aging and wellness platforms.- Flcube.com
